{
    "clinical_study": {
        "@rank": "68723", 
        "arm_group": [
            {
                "arm_group_label": "Intralipid", 
                "arm_group_type": "Experimental", 
                "description": "IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "No intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "Intralipid infusion can improve the outcome in women with recurrent Unexplained miscarriages\n      undergoing IVF/ICSI cycles."
        }, 
        "brief_title": "Single Dose Intralipid for Recurrent Unexplained Miscarriage", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Abortion, Spontaneous", 
            "Abortion, Habitual"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Abortion, Spontaneous", 
                "Abortion, Habitual"
            ]
        }, 
        "detailed_description": {
            "textblock": "Infertile patients undergoing Intracytoplasmic Sperm Injection (ICSI) cycle with history of\n      recurrent unexplained miscarriages, intralipid will be given to the intervention group."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recurrent unexplained miscarriage (3 or more times) in females attempting IVF / ICSI\n             cycles\n\n        Exclusion Criteria:\n\n          -  Age above forty years old.\n\n          -  Antiphospholipid syndrome (lupus anticoagulant and/or anticardiolipin antibodies [IgG\n             or IgM]); other recognised thrombophilic conditions (testing according to usual\n             clinic practice).\n\n          -  Intrauterine abnormalities (as assessed by ultrasound, hysterosonography,\n             hysterosalpingogram, or hysteroscopy).\n\n          -  Abnormal parental karyotype.\n\n          -  Other identifiable causes of recurrent miscarriages (tests initiated only if\n             clinically indicated) e.g., diabetes, thyroid disease and systemic lupus\n             erythematosus (SLE).\n\n          -  Disturbances of normal fat metabolism such as pathologic hyperlipemia\n\n          -  Allergic to it; or to eggs, soybean oil, or safflower oil.\n\n          -  Severe liver disease, kidney disease, lung disease, anemia, blood clotting disorder."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01788540", 
            "org_study_id": "12013"
        }, 
        "intervention": {
            "arm_group_label": "Intralipid", 
            "description": "IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.", 
            "intervention_name": "Intralipid", 
            "intervention_type": "Drug", 
            "other_name": "intralipid 20%"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Recurrent miscarriage", 
            "Implantation failure", 
            "Intralipid", 
            "ICSI / IVF failure"
        ], 
        "lastchanged_date": "February 8, 2013", 
        "location": {
            "contact": {
                "email": "Dinadakhly@mail.com", 
                "last_name": "Dina M Dakhly, M.D.", 
                "phone": "01003498919", 
                "phone_ext": "+2"
            }, 
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt", 
                    "zip": "12211"
                }, 
                "name": "Kasr el ainy hospital"
            }, 
            "investigator": {
                "last_name": "Dina M Dakhly, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Role of Single Dose Intralipid in Cases of Recurrent Unexplained Miscarriage Undergoing IVF / ICSI Cycles, a Prospective Randomized Control Study", 
        "other_outcome": [
            {
                "description": "clinical pregnancy continue after 12 weeks gestational age", 
                "measure": "ongoing pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "10 months"
            }, 
            {
                "measure": "abortion rate", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "overall_contact": {
            "email": "Dinadakhly@gmail.com", 
            "last_name": "Dina M Dakhly, M.D.", 
            "phone": "01003498919", 
            "phone_ext": "+2"
        }, 
        "overall_official": {
            "affiliation": "Faculty of medicine , cairo university", 
            "last_name": "Dina M Dakhly, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Positive pregnancy test in blood as measured by quantitative B- hCG level", 
            "measure": "chemical pregnancy rate", 
            "safety_issue": "No", 
            "time_frame": "10 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01788540"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Woman's Health University Hospital, Egypt", 
            "investigator_full_name": "Dina Mohamed Refaat Dakhly", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Confirmed pregnancy at 7 weeks by ultrasound visualization of gestational sac and positive fetal pulsations", 
            "measure": "clinical pregnancy rate,", 
            "safety_issue": "No", 
            "time_frame": "10 months"
        }, 
        "source": "Woman's Health University Hospital, Egypt", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Woman's Health University Hospital, Egypt", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}